Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025BMJ OpenOpen Access

Key informant perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care in Ontario, Canada: a qualitative description study

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlexandra CernatJAJulia AbelsonZSZainab Samaan

Discussion

Loading...

Member takes

Overview

Qualitative analysis reveals key informants support PGx testing for antidepressants in primary care, suggesting its broader implementation may improve patient outcomes.

Key Points

  • Key informants believe PGx testing can improve antidepressant prescribing, enhancing treatment efficacy and tolerability for patients with major depressive disorder.
  • Many participants emphasized the importance of clinician education regarding PGx testing and identified barriers to accessing this technology in primary care settings.
  • Using semistructured interviews with 28 key informants, this qualitative study gathered insights on the implementation of PGx testing in Ontario's primary care.
  • Findings indicate an overall enthusiasm for PGx testing, yet highlight the need for comprehensive implementation strategies to address concerns and enhance accessibility.

Cite This Study

Cernat et al. (2025) studied this question.

synapsesocial.com/papers/68c238d2b210217d64778d37https://doi.org/10.1136/bmjopen-2024-091562
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1177. A GENETICALLY INFORMED APPROACH TO ANTIDEPRESSANT PRESCRIPTION FOR YOUTH WITH MAJOR DEPRESSIVE DISORDER2025
  2. 2Real‐World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children2025
  3. 3Implementing pharmacogenetic testing in community pharmacy practice: a scoping review2025
  4. 4561. PHARMACOGENETIC-SUPPORTED PRESCRIBING FOR KIDS WITH MENTAL HEALTH CONDTIONS2025
  5. 5Genotype-guided pharmacotherapy: the challenges of integrating pharmacogenomic testing into routine healthcare with a focus on experiences at a single site.2025 · 6 citations